April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Relationship Between Pigment Epithelium-Derived Factor (PEDF) in the Blood and Renal Function in Patients With Diabetic Retinopathy
Author Affiliations & Notes
  • N. Ogata
    Ophthalmology, Kansai Medical University, Moriguchi, Japan
  • K. Matsuyama
    Ophthalmology, Kansai Medical University, Moriguchi, Japan
  • M. Matsuoka
    Ophthalmology, Kansai Medical University, Moriguchi, Japan
  • M. Wada
    Ophthalmology, Kansai Medical University, Moriguchi, Japan
  • K. Takahashi
    Ophthalmology, Kansai Medical University, Hirakata, Japan
  • M. Matsumura
    Ophthalmology, Kansai Medical University, Hirakata, Japan
  • Footnotes
    Commercial Relationships  N. Ogata, None; K. Matsuyama, None; M. Matsuoka, None; M. Wada, None; K. Takahashi, None; M. Matsumura, None.
  • Footnotes
    Support  A Grant-in Aid for Scientific Research from the Ministry of Education in Japan
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1336. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Ogata, K. Matsuyama, M. Matsuoka, M. Wada, K. Takahashi, M. Matsumura; Relationship Between Pigment Epithelium-Derived Factor (PEDF) in the Blood and Renal Function in Patients With Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1336.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Diabetic retinopathy (DR) and nephropathy are major microvascular complications in patients with diabetes, and they are considered to be related. Pigment epithelium-derived factor (PEDF) is a strong inhibitor of angiogenesis, and earlier studies showed that PEDF was significantly elevated in the blood of diabetic patients especially those with proliferative diabetic retinopathy (PDR). The level of PEDF in the blood, on the other hand, was reported to be low in an animal model of diabetic nephropathy. The aim of this study was to determine the relationship between PEDF in the blood and renal function in patients with DR.

Methods: : A total of 243 type 2 diabetic patients were studied. The relationship between the DR and the levels of PEDF in the blood, HbA1c, blood urea nitrogen (BUN), and creatinine were evaluated. The plasma level of PEDF was measured by ELISA, and the stage of DR was determined by ophthalmic examinations. The data were analyzed statistically by one way analysis of variance (ANOVA) with Fisher’s PSLD test and Pearson's product moment correlation coefficient (r).

Results: : The mean plasma PEDF level in patients with PDR (7.69 ± 6.14 µg/ml; means ± standard error) was significantly higher than that of mild to moderate nonproliferative DR (M-NPDR) (5.07 ± 4.37 µg/ml, P = 0.02). The level of BUN and creatinine increased as the stage of DR advanced. The level of BUN in the PDR group (27.1 ± 2.5 mg/dl) was significantly higher than that in the no apparent DR (NDR) (15.6 ± 1.0 mg/dl), M-NPDR (18.5 ± 1.1 mg/dl), and the severe nonproliferative DR (S-NPDR) groups (19.9 ± 0.9 mg/dl, P = 0.002, P = 0.01, P = 0.003, respectively). The level of creatine in the PDR (1.94 ± 0.30 mg/dl) group was significantly higher than that in NDR (0.69 ± 0.06 mg/dl), M-NPDR (0.71 ± 0.06 mg/dl), and S-NPDR (1.01 ±0.19 mg/dl, P = 0.01, P = 0.005, P = 0.008, respectively) groups. The plasma PEDF levels were significantly correlated with the levels of BUN and creatinine (r = 0.54, P < 0.0001; r = 0.57, P < 0.0001, respectively).

Conclusions: : The levels of plasma PEDF increases with advances in both DR and nephropathy. Thus, increased levels of PEDF in the blood may indicate microvascular damages in diabetic patients and may be a predictor of the progression of retinopathy and nephropathy.

Keywords: diabetic retinopathy • diabetes • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×